Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

To be considered for this study, you must be at least 6 years old. If you are an adult or teenager (aged 12 or older), you should have moderate to severe eczema and have recently started Dupilumab. If you are a child between 6 and 11 years old, you should have severe eczema and have recently started Dupilumab. You, or your parent/guardian if you are a child, must be able to understand and fill out some questionnaires related to the study. Finally, you or your parent/guardian will need to give written permission to take part.

There are a few reasons why someone might not be able to join. You cannot participate if your doctor believes Dupilumab is not suitable for you for any reason, or if you have already been taking Dupilumab for more than 7 days. Also, if you have other health problems that would make it difficult for you to complete the study questionnaires, or if your doctor thinks it would affect the results, you won't be able to take part. Lastly, if you are already involved in another similar study that your doctor thinks might affect the results of this one, you would not be eligible.

If you join this study, your involvement will last for up to two years, or until you stop taking Dupilumab, whichever comes first. This is an observational study, so you won't be given any new medication by the study itself; you will continue to receive Dupilumab as prescribed by your doctor as part of your usual care. You'll attend your regular doctor's appointments as you normally would for your eczema treatment. At these appointments, researchers will collect information about your eczema symptoms, how you're feeling, and your quality of life using questionnaires. The study simply records information during your routine visits, so no extra visits are needed beyond your standard care.